Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat

Experimental autoimmune neuritis (EAN) is an animal model for Guillain-Barré syndrome (GBS). Intravenous immunoglobulins (IVIg) are an effective treatment for GBS, but their mechanism of action is not well understood. Here we tested whether IVIg treatment, a potent modulator of proinflammatory assau...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroimmunology Vol. 76; no. 1; pp. 112 - 116
Main Authors Enders, U, Toyka, K.V, Hartung, H.-P, Gold, R
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.06.1997
Subjects
Animals
Female
Guillain-Barré syndrome
Immune globulin
Immunoglobulins, Intravenous - therapeutic use
Neuritis
Neuritis, Autoimmune, Experimental - therapy
Polyradiculoneuropathy - therapy
Rats
Rats, Inbred Lew
Neuritis
Guillain-Barré syndrome
Immune globulin
Online AccessGet full text

Cover

More Information
Summary:Experimental autoimmune neuritis (EAN) is an animal model for Guillain-Barré syndrome (GBS). Intravenous immunoglobulins (IVIg) are an effective treatment for GBS, but their mechanism of action is not well understood. Here we tested whether IVIg treatment, a potent modulator of proinflammatory assaults, reduces inflammation in EAN. The evaluation of IVIg treatment failed to demonstrate a salutary effect in different models of EAN. IVIg appears not to suppress the acute inflammatory insult on the peripheral nerve, but may have beneficial long-term effects not looked for in the present investigation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0165-5728
1872-8421
DOI:10.1016/S0165-5728(97)00039-8